Neonatal diabetes with end-stage nephropathy: pancreas transplantation decision

Diabetes Care. 2008 Nov;31(11):2116-7. doi: 10.2337/dc08-0823. Epub 2008 Aug 4.

Abstract

Objective: To describe the diagnosis of a patient with neonatal diabetes who had been misdiagnosed with type 1 diabetes and referred to our hospital for pancreas and kidney transplantation because of end-stage renal disease.

Research design and methods: A diagnosis of neonatal diabetes was made after a molecular genetic study revealed a mutation in exon 34 of the ABCC8 gene. Pancreas transplantation was ill-advised.

Results: The patient was switched from insulin to glibenclamide 4 months after kidney transplantation, confirming that pancreas transplantation would not have been a good decision.

Conclusions: This is the first report of a patient with neonatal diabetes who developed diabetic nephropathy that progressed to end-stage renal disease. This report illustrates that careful endocrinological evaluation, including molecular genetic studies, if necessary, is mandatory before a decision to perform a pancreas transplant is made.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Diabetes Mellitus, Type 1 / complications
  • Diabetes Mellitus, Type 1 / diagnosis
  • Diabetes Mellitus, Type 1 / therapy*
  • Diabetic Nephropathies / etiology
  • Diabetic Nephropathies / therapy*
  • Follow-Up Studies
  • Glyburide / therapeutic use
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Infant, Newborn
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / therapy*
  • Kidney Transplantation
  • Male
  • Pancreas Transplantation
  • Treatment Outcome

Substances

  • Hypoglycemic Agents
  • Glyburide